Drug Interactions with Antifungals in Veterinary Patients: Azoles and Beyond

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Azole antifungals (ketoconazole, itraconazole, fluconazole, voriconazole) are potent inhibitors of cytochrome P450 (CYP) enzymes and drug transporters, leading to significant drug interactions in veterinary patients. Ketoconazole is a particularly strong CYP3A inhibitor in dogs, while fluconazole exhibits weaker CYP inhibition but affects renal transporters.
• Interactions with azoles can lead to altered exposure of co-administered drugs, such as increased concentrations of immunosuppressants (cyclosporine, tacrolimus) and anticonvulsants (phenobarbital), necessitating dose adjustments and close monitoring of drug levels and clinical signs.
• Gastric pH significantly impacts the absorption of certain azoles; itraconazole capsules and ketoconazole bioavailability are reduced by gastric acid suppressants (PPIs, H2 antagonists), while fluconazole's absorption is largely unaffected due to its high aqueous solubility.
• Beyond azoles, echinocandins and ibrexafungerp exhibit minimal CYP enzyme inhibition, resulting in fewer clinically significant drug interactions, making them potentially safer choices in polypharmacy scenarios. Amphotericin B's primary interaction risk is additive nephrotoxicity rather than metabolic pathways.
• Management of antifungal drug interactions requires a comprehensive medication reconciliation, identification of potential CYP or transporter interactions, and a proactive approach involving dose adjustments, therapeutic drug monitoring (TDM) where available, and vigilant clinical monitoring for adverse effects or therapeutic failures.
• Species-specific differences in drug metabolism (e.g., lower CYP3A2 activity in cats compared to dogs) can amplify the magnitude of azole-induced drug interactions, requiring tailored monitoring and drug selection strategies.

Systemic antifungal therapy in veterinary patients frequently accompanies chronic disease, polypharmacy, and compromised host status. The azole class, including ketoconazole, itraconazole, fluconazole, and voriconazole, carries the highest interaction burden because these drugs inhibit cytochrome P450 enzymes and drug transporters in a species-variable manner. This article reviews the mechanisms, clinical consequences, and management of antifungal drug interactions across dogs, cats, horses, and exotic species. It serves the practitioner who must anticipate adverse effects, adjust concomitant medications, or interpret unexpected therapeutic failures when an azole is added to an existing regimen. The focus is on interactions that change drug exposure or toxicity risk, with attention to the evidence base, which ranges from controlled human pharmacokinetic studies to extrapolated veterinary case experience.

The azoles are not interchangeable in their interaction profiles. Ketoconazole is the most potent CYP3A inhibitor in dogs, whereas fluconazole is a weaker enzyme inhibitor but a substrate and inhibitor of renal transporters. Itraconazole inhibits CYP3A and P-glycoprotein, and its oral absorption depends on gastric pH. Voriconazole inhibits CYP2C19, CYP3A4, and CYP2C9 in humans, but its veterinary use is limited by cost and species-specific toxicity. Beyond the azoles, the echinocandins and the newer triterpenoid ibrexafungerp have comparatively few drug interactions because they do not meaningfully inhibit cytochrome P450 enzymes, although they share the glucan synthase target with the echinocandins. Amphotericin B interacts primarily through additive nephrotoxicity instead of metabolic pathways. The polyene and echinocandin classes are reviewed in the context of combination therapy, where additive or synergistic antifungal effects must be weighed against overlapping toxicity.

At a Glance

Mechanisms of Antifungal Drug Interactions

Cytochrome P450 Inhibition and Induction

The imidazole and triazole antifungals bind to fungal lanosterol 14-alpha-demethylase, but they also coordinate with the heme iron of mammalian cytochrome P450 enzymes. Ketoconazole and itraconazole are the most potent inhibitors of CYP3A isoforms in dogs and cats, with ketoconazole showing the highest affinity. This inhibition is noncompetitive and rapid in onset, reaching clinically relevant magnitude within days of initiating therapy. Fluconazole is a weaker CYP3A inhibitor but inhibits CYP2C9 and CYP2C19 at therapeutic concentrations, which matters in species where those isoforms carry significant drug metabolism. Voriconazole inhibits multiple CYP isoforms and also undergoes saturable metabolism, creating nonlinear pharmacokinetics that complicate dose prediction.

Induction is less common among the azoles but occurs with rifampin co-administration, which upregulates CYP3A and P-glycoprotein expression and can reduce itraconazole and ketoconazole exposure below therapeutic thresholds. Phenobarbital similarly induces CYP3A in dogs and can shorten azole half-lives. The interaction is bidirectional: the azole inhibits phenobarbital metabolism while phenobarbital induces azole clearance, producing unpredictable net effects that require drug level monitoring.

P-glycoprotein and Transporter Interactions

P-glycoprotein is an efflux transporter expressed in the intestinal epithelium, blood-brain barrier, renal tubules, and hepatocytes. Itraconazole and ketoconazole inhibit P-glycoprotein at concentrations achieved with standard dosing, increasing the oral absorption and central nervous system penetration of substrates such as ivermectin, loperamide, and some chemotherapeutic agents. In dogs with the MDR1 mutation, the combination of an azole with a P-glycoprotein substrate can produce neurotoxicity at doses that would otherwise be tolerated. Fluconazole does not meaningfully inhibit P-glycoprotein but interacts with organic cation transporters in the kidney, which explains its effect on renal clearance of some drugs.

pH-Dependent Absorption

Itraconazole capsules require gastric acid for dissolution. Proton pump inhibitors, H2 antagonists, and antacids reduce itraconazole bioavailability by up to 50 percent in human studies, and similar effects are assumed in dogs and cats. The oral solution of itraconazole uses hydroxypropyl-beta-cyclodextrin and is less pH-dependent, but it is not licensed for veterinary use in all regions. Ketoconazole absorption also declines with elevated gastric pH, although the clinical magnitude is smaller. Fluconazole absorption is unaffected by gastric pH because of its high aqueous solubility.

Azole Interactions with Immunosuppressants

Cyclosporine and tacrolimus are the most clinically consequential azole interactions in veterinary dermatology and transplantation. Ketoconazole co-administration reduces cyclosporine clearance by 50 to 80 percent in dogs, allowing cyclosporine dose reduction of 50 to 75 percent, a strategy sometimes used deliberately to reduce treatment cost. The same interaction applies to tacrolimus, with a narrower therapeutic index and greater risk of nephrotoxicity. The magnitude of the interaction is dose-dependent and stabilizes after 5 to 7 days of co-administration. Monitoring cyclosporine trough levels is mandatory when azoles are added or withdrawn, because the cyclosporine dose must be adjusted in both directions. Fluconazole produces a smaller but still significant increase in cyclosporine exposure, whereas the echinocandins do not interact with cyclosporine metabolism, although caspofungin and cyclosporine co-administration carries a historical warning about hepatic enzyme elevation.

Azole Interactions with Cardiac and Gastrointestinal Drugs

Cisapride is contraindicated with ketoconazole and itraconazole because CYP3A inhibition prolongs the QT interval and risks ventricular arrhythmias. This combination is now rarely encountered because cisapride was withdrawn from many markets, but compounded formulations still appear in practice. Other QT-prolonging drugs, including some macrolides and fluoroquinolones, should be used with caution and electrocardiographic monitoring when combined with azoles. The azoles themselves prolong the QT interval in a concentration-dependent manner, and additive effects with antiarrhythmic drugs such as amiodarone or sotalol warrant baseline and follow-up electrocardiography.

Metoclopramide and proton pump inhibitors do not interact metabolically with azoles, but the gastric acid suppressants reduce itraconazole absorption as described. Sucralfate and oral iron products bind azoles in the gastrointestinal tract and should be separated by at least two hours.

Azole Interactions with Anticonvulsants and Other CNS-Active Drugs

Phenobarbital is a potent inducer of cytochrome P450 enzymes, particularly CYP3A isoforms, and it accelerates the metabolism of ketoconazole, itraconazole, and voriconazole. In dogs receiving both drugs, serum azole concentrations may fall below therapeutic thresholds, risking breakthrough fungal infection. The interaction is bidirectional: ketoconazole and itraconazole inhibit phenobarbital metabolism, raising barbiturate concentrations and increasing the risk of sedation, ataxia, and hepatotoxicity. When the combination cannot be avoided, measure serum phenobarbital concentrations 10 to 14 days after starting the azole and again after any dose adjustment. If therapeutic drug monitoring for the azole is unavailable, consider fluconazole, which is less dependent on CYP3A for clearance and produces a weaker inhibitory effect on phenobarbital metabolism. Fluconazole is not free of interaction, however, and phenobarbital concentrations should still be rechecked.

Zonisamide undergoes hepatic metabolism with contributions from CYP3A and N-acetyltransferase. Azole inhibition of CYP3A can raise zonisamide concentrations, although clinical reports in veterinary patients are limited. Monitor for increased sedation and consider reducing the zonisamide dose by 20 to 30 percent when starting itraconazole or ketoconazole, with dose titration guided by clinical response and, where available, serum drug concentrations. Levetiracetam is largely renally excreted and is the anticonvulsant least likely to interact with azoles. For epileptic dogs requiring systemic antifungal therapy, levetiracetam is a reasonable first choice when anticonvulsant selection is open.

Trazodone is metabolised by CYP3A and is commonly prescribed in dogs for anxiety and activity restriction. Concurrent itraconazole or ketoconazole can increase trazodone exposure, producing excessive sedation or serotonin-related signs. Reduce the trazodone dose by roughly half when starting a potent CYP3A-inhibiting azole, and titrate to effect. Fluconazole at standard doses has less impact on trazodone metabolism. Acepromazine is also CYP3A-metabolised, enhanced sedation is possible but usually mild and manageable by dose reduction.

Azole Interactions with Antimicrobials

Rifampin is a strong CYP3A inducer and reduces itraconazole and ketoconazole concentrations substantially, often to subtherapeutic levels. This combination is particularly problematic in treating deep mycoses where rifampin is used for concurrent bacterial infection. Where possible, substitute another antibacterial. If rifampin must continue, increase the azole dose and monitor clinical response closely, serum azole concentration measurement is strongly advised where available. Fluconazole is less affected but still shows reduced exposure with rifampin.

Fluoroquinolones and azoles share QT-prolonging potential, and concurrent use increases the risk of ventricular arrhythmias, particularly in patients with underlying cardiac disease or electrolyte disturbances. This is a pharmacodynamic interaction instead of a pharmacokinetic one. When combining these drugs, assess baseline cardiac status, correct hypokalemia and hypomagnesemia before starting therapy, and consider electrocardiographic monitoring in high-risk patients. The same precaution applies to azole combinations with macrolides such as clarithromycin, which also inhibits CYP3A and can raise azole concentrations while adding QT risk.

Sulfonamide-containing antimicrobials, including potentiated sulfonamides, can inhibit CYP enzymes and may increase azole concentrations. Clinical significance in veterinary patients is uncertain, but monitoring for azole adverse effects is prudent when these drugs are combined. Metronidazole does not meaningfully interact with azoles through cytochrome pathways, although both drugs can cause hepatotoxicity, and liver enzyme monitoring is reasonable during prolonged concurrent use.

Azole Interactions with Antiparasitic Drugs

Ivermectin and milbemycin are substrates of P-glycoprotein, and azoles that inhibit this transporter, particularly ketoconazole and itraconazole, can increase central nervous system penetration of these macrocyclic lactones. In dogs with normal ABCB1 (MDR1) status, the effect is usually modest, but in dogs with the ABCB1-1 delta mutation, concurrent use can precipitate neurotoxicity at standard doses. For collies and other breeds at risk, genotype testing before combined therapy is advisable. If the combination is necessary, reduce the macrocyclic lactone dose, monitor for mydriasis, ataxia, and tremors, and discontinue the azole if signs develop.

Praziquantel is metabolised by hepatic cytochrome enzymes, and ketoconazole can increase its systemic exposure. The clinical significance is generally low because praziquantel has a wide safety margin in dogs and cats. Fenbendazole and other benzimidazoles have minimal documented interactions with azoles. The combination of azoles with amiodarone or other potent CYP inhibitors used for antiparasitic purposes is not a recognized clinical scenario, but the general principle of additive enzyme inhibition applies when multiple inhibitors are co-prescribed.

Antifungal Combinations: Azoles with Other Antifungals

Combining azoles with amphotericin B is generally avoided because azoles inhibit ergosterol synthesis, and amphotericin B requires ergosterol in the fungal cell membrane for its binding and pore-forming action. In vitro studies have not consistently demonstrated antagonism, and some data suggest indifference, but the theoretical basis for avoidance remains in standard teaching. Where combination therapy is considered for refractory infections, sequential instead of concurrent administration is often recommended, with amphotericin B given first.

Azole and echinocandin combinations have been studied primarily in human medicine. In vitro work with anidulafungin and azoles against Candida species showed additive activity or indifference, with no antagonism observed across the isolates tested in vitro interaction studies of anidulafungin with azoles and amphotericin B. For Mucorales infections, combination data from experimental models show that most antifungal drug interactions are indifferent, with some synergistic combinations of echinocandins with azoles or amphotericin B, and no antagonism reported antifungal combination studies in Mucorales. These findings support the use of azole-echinocandin combinations in selected refractory cases, particularly where monotherapy has failed or where resistance is suspected. The echinocandins have a distinct mechanism, inhibition of beta-(1,3)-D-glucan synthase, which leaves the azole target unaffected and explains the absence of antagonism review of echinocandin pharmacology and clinical use.

Combinations of azoles with flucytosine are occasionally used for cryptococcal infections, particularly in cats. Flucytosine is renally excreted, and azoles do not meaningfully alter its clearance. The combination is generally well tolerated, but flucytosine carries a risk of myelosuppression and gastrointestinal toxicity, and hematologic monitoring is recommended during therapy.

Practical Management of Antifungal Drug Interactions

A structured approach reduces the risk of adverse outcomes. Before prescribing an azole, compile a complete medication list including topical products, supplements, and any drugs administered by referring veterinarians. Identify the cytochrome P450 and transporter profile of each drug, and flag combinations where the azole is a substrate, inhibitor, or inducer of the relevant pathway.

When an interaction is identified, first determine whether the combination can be avoided by substituting a drug from a different class. Fluconazole is often the least interactive azole because it is a weaker CYP3A inhibitor than ketoconazole or itraconazole, although it retains clinically relevant effects at higher doses. Where substitution is not possible, adjust doses based on the expected direction of the interaction, monitor clinical response and adverse effects, and use therapeutic drug monitoring where available. The evidence base for many interactions in veterinary patients is extrapolated from human medicine, and the magnitude of effect varies between species and between individual animals review of antifungal pharmacology and drug interactions in animals. Document the interaction, the rationale for the chosen management, and the monitoring plan in the medical record. Recheck drug concentrations and clinical status at intervals appropriate to the drugs involved, typically 7 to 14 days after any change.

Recognized Complications and Failure Modes

The most consequential failure in antifungal therapy is unrecognised underdosing of a co-administered drug whose metabolism is induced by an azole. Phenobarbital and rifampin lower azole concentrations through CYP induction, and the reverse direction, azole-mediated inhibition of CYP3A4, raises concentrations of ciclosporin, tacrolimus, and sildenafil to potentially toxic levels. Detection depends on scheduled therapeutic drug monitoring where assays exist, and on clinical vigilance for dose-dependent toxicity in the absence of monitoring. For ciclosporin, measure trough concentrations within five to seven days of starting or stopping an azole. For phenobarbital, measure serum concentrations if seizure control deteriorates or sedation deepens unexpectedly.

A second recognized failure mode is the assumption that fluconazole is free of interactions because it is a weaker CYP inhibitor than ketoconazole or itraconazole. Fluconazole inhibits CYP2C9 and CYP3A4 at clinically used doses, and case-based evidence in human medicine has established interactions with warfarin and phenytoin. In veterinary patients, the same enzyme systems apply, and the safe approach is to treat fluconazole as an interaction-capable drug, particularly in cats receiving chronic therapy.

A third failure mode is the pH-dependent absorption trap. Gastric acid suppression with proton pump inhibitors or H2 antagonists reduces the bioavailability of itraconazole capsules and ketoconazole. The clinician who sees a poor response to an azole should ask whether the patient is receiving a gastroprotectant before increasing the dose. The discriminating check is to review the complete medication list, also the antifungal prescription.

Common Errors and Corrective Actions

Less experienced clinicians frequently omit a complete medication reconciliation before starting an azole. The corrective action is a structured review of every prescription, over-the-counter product, and topical preparation, because topical ketoconazole and miconazole can inhibit CYP enzymes and P-glycoprotein. A second common error is stopping an interacting drug abruptly when the interaction is identified. The safer sequence is to adjust the interacting drug dose, recheck the relevant laboratory parameter, and then taper the azole if it is no longer needed.

A third error is extrapolating human interaction data to veterinary species without adjustment for species differences in metabolism. Cats are particularly sensitive to azole toxicity because of their reduced glucuronidation capacity, and dogs metabolise some azoles more rapidly than humans. The corrective action is to consult species-specific pharmacology references such as the MSD Veterinary Manual and to use therapeutic drug monitoring where available.

Limitations of the Evidence and Areas of Disagreement

The evidence base for antifungal interactions in veterinary patients is largely extrapolated from human medicine and from in vitro studies. In vitro checkerboard data, such as those examining antifungal combinations in Mucorales and interactions of anidulafungin with azoles against Candida species, provide useful direction but do not predict clinical outcomes in dogs and cats. In vitro synergy does not guarantee in vivo benefit, and indifference in vitro does not exclude a clinically relevant interaction.

Expert opinion differs on the value of routine combination antifungal therapy. Some authorities advocate dual azole-echinocandin therapy for refractory Aspergillus infections, while others reserve combinations for confirmed resistance or treatment failure. The review of echinocandins as the newest antifungal class summarizes the pharmacodynamic rationale but does not resolve the clinical question. Similarly, the in vitro synergy between antituberculous drugs and antifungals against Coccidioides posadasii has not been translated into veterinary protocols, and clinicians should not adopt such combinations without specialist guidance.

Escalation and Referral

Referral or specialist consultation is warranted when an interaction produces severe toxicity, when therapeutic drug monitoring is unavailable but the interacting drug has a narrow therapeutic index, or when the patient fails to respond despite appropriate dose adjustment. Clinical pharmacologists and veterinary teaching hospitals can provide population pharmacokinetic data and assay support that is not available in general practice.

Laboratory involvement is indicated for monitoring ciclosporin, tacrolimus, phenobarbital, and azole concentrations, and for assessing hepatic function during prolonged azole therapy. The FDA Center for Veterinary Medicine provides adverse event reporting pathways for suspected drug interactions, and clinicians should report unexpected toxicities even when causality is uncertain. Regulatory reporting obligations differ by jurisdiction, and the WOAH terrestrial animal health standards apply to production animals where withdrawal periods and residue concerns interact with antifungal use. Antimicrobial stewardship principles, as outlined by the AVMA, support the judicious use of antifungals and the documentation of treatment rationale when interactions complicate therapy.

Frequently Asked Questions

How should I adjust monitoring when an azole is added to a regimen containing a narrow-therapeutic-index drug?

Add the azole, then recheck the narrow-therapeutic-index drug at its next scheduled trough or peak, not two weeks later. For ciclosporin, measure trough concentration within 3 to 5 days of starting itraconazole or ketoconazole and again after any dose change. For digoxin, check serum concentration 5 to 7 days after fluconazole initiation, since fluconazole reduces digoxin clearance. For phenobarbital, measure serum levels 7 to 10 days after adding an azole, because enzyme induction may lower azole exposure while phenobarbital levels rise. Document the interaction in the record, and instruct the owner to watch for clinical signs of toxicity in the interim. The FDA Center for Veterinary Medicine maintains adverse event reporting pathways for suspected interactions.

What can I do when therapeutic drug monitoring is unavailable or unaffordable?

Use clinical surrogates and conservative dosing. For ciclosporin, monitor for gingival hyperplasia, vomiting, and hirsutism as toxicity markers, and reduce the dose by 30 to 50% empirically when adding ketoconazole. For digoxin, follow appetite, heart rate, and rhythm, bradyarrhythmia or anorexia warrants dose reduction. For phenobarbital, track sedation and ataxia. When laboratory access is limited, choose fluconazole over ketoconazole or itraconazole for patients on CYP3A4 substrates, because fluconazole is a weaker inhibitor at standard doses. The MSD Veterinary Manual provides species-specific guidance on clinical monitoring when drug assays are not practical.

Does the interaction profile differ between cats and dogs in ways that change my drug choice?

Yes. Cats have lower CYP3A2 activity than dogs, so azole inhibition of this pathway produces more pronounced elevations of co-administered substrates such as ciclosporin and methadone. Fluconazole is often preferred in cats because it is renally cleared and less CYP-dependent, but it still inhibits CYP2C and CYP3A. Itraconazole causes more gastrointestinal intolerance in cats, which can reduce compliance and complicate assessment of adverse effects. In dogs, ketoconazole is a more potent CYP3A inhibitor than itraconazole and is commonly used deliberately to reduce ciclosporin cost. Species-specific dosing and monitoring recommendations are available through the MSD Veterinary Manual.

How should I document an antifungal interaction in the medical record?

Record the indication for the azole, the interacting drug, the start and stop dates of each, and the specific monitoring plan. Note the expected direction of the interaction, for example increased ciclosporin exposure, and the clinical signs you instructed the owner to report. If you adjusted a dose, state the rationale and the follow-up interval. Include a plan for rechecking laboratory values or drug concentrations. This documentation supports continuity if another clinician assumes the case and provides a defensible record if an adverse event occurs. The AVMA practice resources offer guidance on medical record standards and adverse event documentation.

How do I explain a drug interaction to a client without causing them to stop the medication?

Use concrete language. Tell the owner that the antifungal changes how the body processes the other drug, so the other drug may need a lower dose or closer watching. Give them a specific list of signs to report, such as vomiting, lethargy, or changes in drinking and urinating. Explain that stopping the antifungal without veterinary direction can cause the fungal infection to worsen and can also destabilise the other drug's levels. Reassure them that dose adjustments are routine and that you will recheck at a defined date. The AVMA antimicrobial stewardship resources emphasize clear communication as part of responsible antifungal use.

When is it appropriate to refer a case involving an antifungal interaction?

Refer when the interacting drug has a narrow therapeutic index and you cannot obtain timely drug concentration monitoring, when the patient has renal or hepatic disease that complicates dose adjustment, or when the fungal infection is not responding despite appropriate therapy. Refer also when the patient requires a combination of antifungals, such as an azole with an echinocandin for resistant mould infection, because the evidence for benefit is limited to specific contexts and the interaction risk is higher. The WOAH terrestrial animal health standards and FDA Center for Veterinary Medicine provide frameworks for reporting treatment failures and adverse events that may inform referral decisions.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Antifungal combinations in Mucorales: A microbiological perspective.. 2019.
• In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii.. 2009.
• In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.. 2006.
• Echinocandins: the newest class of antifungals.. 2009.
• Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.. 2022.
• Antifungal agents of use in animal health--chemical, biochemical and pharmacological aspects.. 2003.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Drug Interactions with Antihypertensive Medications in Veterinary Patients
• Drug Interactions with Antacids and Gastroprotectants in Veterinary Patients
• Drug Interactions with Anticonvulsant Medications in Veterinary Patients: Phenobarbital, Potassium Bromide, and Levetiracetam
• Drug Interactions with Antiemetics in Veterinary Patients: Clinical Considerations
• Drug Interactions with Antithrombotic and Antiplatelet Agents in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.